指南与共识胸部心血管外周血管CTMRUS

2020年中国专家共识:结缔组织病相关肺动脉高压的诊断与治疗

2020 Chinese Expert-based Consensus on the Diagnosis and Treatment of Connective Tissue Disease Associated Pulmonary Arterial Hypertension.
指南 / 共识 · Rheumatol Immunol Res · 2021-09-28

该共识由45名风湿科、心内科、呼吸科和放射科专家组成的多学科小组制定,针对结缔组织病相关肺动脉高压提出9条推荐,涵盖筛查、诊断、疾病评估、风险分层、免疫抑制剂使用及靶向治疗,旨在规范中国CTD-PAH的临床决策。

要点

  • 共识强调对结缔组织病患者进行PAH筛查和早期诊断。
  • 推荐采用风险分层指导和靶向治疗以达到治疗目标。
  • 影像科医生应参与多学科协作,助力CTD-PAH的评估。

诊断标准与关键数值

  • 共识提出9条推荐,涵盖筛查、诊断、疾病评估、风险分层、免疫抑制剂使用和以实现治疗目标为导向的PAH特异性治疗。

临床应用与阅片要点

  • 放射科医生应了解CTD-PAH的筛查和诊断流程,在多学科团队中参与影像评估。
  • 关注共识中涉及的疾病评估和风险分层,以辅助临床决策。

局限性

  • 共识基于专家意见,未报告系统文献回顾和证据分级,推荐强度不确定。
  • 原文未报告具体的影像学诊断标准或数值阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Pulmonary arterial hypertension (PAH) is a severe complication of connective tissue disease (CTD) and is one of the leading causes of morbidity and mortality among patients with this condition. To establish an expert-based consensus on the diagnosis and treatment of CTD-associated PAH, a multidisciplinary consensus development panel was established. The consensus panel is composed of 45 experts in rheumatology, cardiology, pulmonology, and radiology, most of whom are members of the Group of Pulmonary Vascular and Interstitial Lung Diseases (ILD) Associated with Rheumatic Diseases. The consensus development panel compiled 9 recommendations for the diagnosis and treatment of CTD-associated PAH. It covers screening, diagnosis, disease evaluation, risk assessment, the use of immunosuppressive agents, and PAH-specific therapy with a treat-to-target approach. The consensus is intended to facilitate decision-making and standardize the care of CTD-associated PAH in China.

来源:Rheumatol Immunol Res,查看原文。版权归原作者所有。

引用

  1. Zhao J, Wang Q, Wang Q, et al. 2020 Chinese Expert-based Consensus on the Diagnosis and Treatment of Connective Tissue Disease Associated Pulmonary Arterial Hypertension. Rheumatol Immunol Res. 2021. PMID: 36465975. doi:10.2478/rir-2021-0010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。